References
- Kandakatla N, Ramakrishnan G, Karthikeyan J, Chekkara R. Pharmacophore modeling, atom based 3D-QSAR and docking studies of chalcone derivatives as tubulin inhibitors. Orient J Chem 2014;30:1083–98.
- Sutkovic J. In silico prediction of three-dimensional structure and interactome analysis of Tubulin Alpha subfamily of Arabidopsis thaliana. Netw Biol 2014;4:47.
- Lu Y, Chen J, Xiao M, et al. An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm Res 2012;29:2943–71.
- Li DD, Qin YJ, Zhang X, et al. Combined molecular docking, 3D‐QSAR, and pharmacophore model: design of novel tubulin polymerization inhibitors by binding to colchicine‐binding site. Chem Biol Drug Des 2015;86:731–45.
- Choudhury GG, Banerjee A, Bhattacharyya B, Biswas BB. Interaction of colchicine analogues with purified tubulin. FEBS Lett 1983;161:55–9.
- Jin Y, Qi P, Wang Z, et al. 3D-QSAR study of combretastatin A-4 analogs based on molecular docking. Molecules 2011;16:6684–700.
- Ravelli RB, Gigant B, Curmi PA, et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004;428:198–202.
- Zardiny Z, Gholami S, Ramazani MA. Structure activity relationship (SAR) investigation on the binding properties of ligands similar to combretastatin to colchicine binding site of tubulin protein as anti-cancer drug. Res Pharm Sci 2012;7:S568.
- Attia SM. Molecular cytogenetic evaluation of the mechanism of genotoxic potential of amsacrine and nocodazole in mouse bone marrow cells. J Appl Toxicol 2013;33:426–33.
- Lu Y, Li CM, Wang Z, et al. Discovery of 4-substituted methoxybenzoyl-aryl-thiazole as novel anticancer agents: synthesis, biological evaluation, and structure–activity relationships. J Med Chem 2009;52:1701–11.
- Rischin D, Bibby DC, Chong G, et al. Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation. Clin Cancer Res 2011;17:5152–60.
- Bailly C, Bal C, Barbier P, et al. Synthesis and biological evaluation of 4-arylcoumarin analogs of combretastatins. J Med Chem 2003;46:5437–44.
- Flynn BL, Flynn GP, Hamel E, Jung MK. The synthesis and tubulin binding activity of thiophene-based analogues of combretastatin A-4. Bioorg Med Chem Lett 2001;11:2341–3.
- Wang L, Woods KW, Li Q, et al. Potent, orally active heterocycle-based combretastatin A-4 analogs: synthesis, structure–activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation. J Med Chem 2002;45:1697–711.
- Johnson M, Younglove B, Lee L, et al. Design, synthesis, and biological testing of pyrazoline derivatives of combretastatin-A4. Bioorg Med Chem Lett 2007;17:5897–901.
- Ruprich J, Prout A, Dickson J, et al. Design, synthesis and biological testing of cyclohexenone derivatives of combretastatin-A4. Lett Drug Des Discov 2007;4:144–8.
- Montes-Avila J, Díaz-Camacho SP, Sicairos-Félix J, et al. Solution-phase parallel synthesis of substituted chalcones and their antiparasitary activity against Giardia lamblia. Bioorg Med Chem 2009;17:6780–5.
- Dassault Systèmes BIOVIA. Discovery studio modeling environment, Release 4. San Diego, CA: Dassault Systèmes; 2015.
- Shakil N, Singh MK, Sathiyendiran M, et al. Microwave synthesis, characterization and bio-efficacy evaluation of novel chalcone based 6-carbethoxy-2-cyclohexen-1-one and 2H-indazol-3-ol derivatives. Eur J Med Chem 2013;59:120–31.
- Botta M, Forli S, Magnani M, Manetti F. Molecular modeling approaches to study the binding mode on tubulin of microtubule destabilizing and stabilizing agents. In: Carlomagno T, ed. Tubulin-binding agents: synthetic, structural and mechanistic insights. Berlin (Heidelberg): Springer Berlin Heidelberg; 2009:279–328.
- O’Boyle NM, Greene LM, Bergin O, et al. Synthesis, evaluation and structural studies of antiproliferative tubulin-targeting azetidin-2-ones. Bioorg Med Chem 2011;19:2306–25.